Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01791049 · ClinicalTrials.gov registry record · Phase 1
TD-1607 SAD Study in Healthy Subjects
A Phase 1 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01791049 is a Phase 1 study that has completed, run by Theravance Biopharma. The registered enrollment target is 64 participants.
The verdict
NCT01791049, a Phase 1 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
TD-1607, administered intravenously as single doses, will be investigated in healthy subjects to assess its tolerability, safety, and pharmacokinetics.
Interventions
- DRUG Placebo
- DRUG TD-1607
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-04 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01791049
The ClinicalTrials.gov registry entry for NCT01791049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01791049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01791049 about?
NCT01791049 is a clinical study titled "TD-1607 SAD Study in Healthy Subjects". TD-1607, administered intravenously as single doses, will be investigated in healthy subjects to assess its tolerability, safety, and pharmacokinetics.
What is the current status of trial NCT01791049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2013-04. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01791049?
The interventions under investigation include: Placebo (DRUG), TD-1607 (DRUG).
Who is sponsoring clinical trial NCT01791049?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.